Page 24 - MI-1-2

Microbes & Immunity Homologous versus heterologous COVID-19 vaccines

Table 2. (Continued)
No References Country Study design Vaccine (dose) Median age Groups Number of Intervention Interval
(range) subjects between
doses
Non-inferiority, Ad26 (0.5 mL) 61 (21 – 95) Group 2 333 CoronaVac/BNT
Single blind) (heterologous)
ChAd (0.5 mL) 60 (21 – 96) Group 3 296 CoronaVac/ChAd
(heterologous)
BNT (0.3 mL) 58 (21 – 95) Group 4 281 CoronaVac/
(homologous) CoronaVac
8 Firinu Italy Observational BNT (0.3 mL) 33 (IQR 5.2) Group 1 50 BNT/BNT 3 weeks
13
et al., 2021 study (homologous)
ChAd (0.5 mL) 34 (IQR 18) Group 2 36 ChAd/ChAd 8 – 12 weeks
(homologous)
25.2 (IQR 18.8) Group 3 49 ChAd/BNT 8 – 12 weeks
(heterologous)
9 Glöckner Germany Observational BNT (0. 3 mL 45 Group 1 22 BNT/BNT 3 weeks
et al., 2021 study (IQR 30 – 53) (homologous)
14
ChAd (0.5 mL) 36 Group 2 21 ChAd/m1273 or 12 weeks
(IQR 32 – 44) (heterologous) BNT
mRNA-1273
(0.5 mL)
10 Gram Denmark Cohort study ChAd (0.5 mL) 45 Group 1 7809 ChAd/- 8 – 12 weeks
et al., 2021 (IQR 33 – 55) (control)
15
BNT (0. 3 mL) 46 Group 2 88050 ChAd/BNT
(IQR 34 – 55) (heterologous)
mRNA-1273 46 Group 3 48501 ChAd/m1273
(0.5 mL) (IQR 34 – 55) (heterologous)
11 Groß Germany Cohort study ChAd (0.5 mL) 30.5 (25 – 46) Group 1 26 ChAd/BNT 8 weeks
16
et al., 2022 (heterologous)
BNT (0.3 mL) 41 (25 – 65) Group 2 14 BNT/BNT 3 weeks
(homologous)
12 Hillus Germany Prospective ChAd (0.5 mL) 34 (29 – 43) Group 1 174 BNT/BNT 3 weeks
et al., 2021 cohort study (homologous)
17
BNT (0.3 mL) 51 (33 – 59) Group 2 38 ChAd/ChAd 10 – 12 weeks
(homologous)
37 (29 – 51) Group 3 104 ChAd/BNT
(heterologous)
13 Kant et al., India Observational ChAd (0.5 mL) 65.5 (IQR 62 Group 1 40 ChAd/ChAd 6 weeks
18
2021 study – 69) (homologous)
BBV152 (0.5 mL) 56 (IQR 45.5 Group 2 40 BBV152/BBV152 4 weeks
– 63) (homologous)
62 (IQR 54.25 – Group 3 18 ChAd/BBV152 6 weeks
69.75) (heterologous)
14 Khong Hong Kong Prospective CoronaVac 53 (26 – 76) Group 1 15 BNT/BNT/BNT Received first
et al., 2022 cohort study (0.5 mL) (homologous) 2 vaccinations
19
BNT (0.3 mL) 47 (22 – 58) Group 2 5 BNT/CoronaVac/ for>6 months
(heterologous) BNT
(Cont’d...)

Volume 1 Issue 2 (2024) 18 doi: 10.36922/mi.3757